News

Filter

FDA calls for additional Ph III study for Basilea’s ceftobiprole

FDA calls for additional Ph III study for Basilea’s ceftobiprole

26-06-2014

Swiss drugmaker Basilea Pharmaceutica saw its shares drop as much as 12% yesterday, after it revealed…

Antibiotics and Infectious diseasesBacteriaBasilea PharmaceuticaceftobiproleHealth Medical PharmaHealth Medical PharmaisavuconazoleMedicinePharmaceuticalRegulationTreatment of pneumoniaUSA

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Astellas’ antifungal study reports positive results

30-09-2013

Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development

17-07-2013

Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

Edison analysts' take on Basilea outlook

10-09-2012

The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica…

Antibiotics and Infectious diseasesBasilea PharmaceuticaBiotechnologyceftobiproleFinancialisavuconazoleOncologyResearchToctino

GlaxoSmithKline gets global rights to Basilea's Toctino

12-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that its dermatology-focussed subsidiary Stiefel has…

Basilea PharmaceuticaceftobiproleDermatologicalsGlaxoSmithKlineisavuconazoleLicensingPharmaceuticalResearchStiefelToctino

Back to top